Milestone Scientific Inc.

Greetings and welcome to the Milestone Scientific Third Quarter 2025 Financial Results and Business Update call. At this time, all participants are placed on a listen-only mode and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. And please note, this conference is being recorded. I will now turn the conference over to your host, Mr. David Waldman. Sir, the floor is yours.

Thank you. Good morning, and I appreciate everyone joining Milestone Scientific's third quarter 2025 Financial Results Conference call. On the call with us today are Eric Hines, Chief Executive Officer, and Keisha Harkam, Vice President of Finance at Milestone Scientific. The company issued a press release yesterday after market containing third quarter 2025 financial results, which is also posted on the company's website. If you have any questions after the call or would like any additional information about the company, please contact Crescendo Communications at 212-671-1020. The company's management will now provide prepared remarks reviewing the financial and operational results for the third quarter ended September 30th, 2025. Before we get started, we would like to remind everyone that during this conference call, we may make forward-looking statements regarding timing and financial impact of Milestone's ability to implement its business plan, expected revenue, and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive, and market conditions and future business decisions, all of which are difficult or impossible to predict accurately, and many of which are beyond milestones control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time milestones, periodic filings with Securities and Exchange Commission, including without limitation milestones report on Form 10-K for the year ended December 31st. 2024 Milestones Report on Form 10-Q for the third quarter ended September 30, 2025. The forward-looking statements made during this call are based upon management's reasonable belief as of today's date, November 14, 2025. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. With that, we'll now turn the call over to Eric Hein, CEO of Milestone Scientific. Please go ahead, Eric.

Thank you, David. So good morning, folks, and thank you for all joining our call. We're very fortunate to have so many people who believe in Milestone Scientific, and we are making progress. During the third quarter, we continued to execute our plan to build a leaner, more focused organization capable of sustainable growth and improved profitability. Through disciplined cost management and operational restructuring, we reduced operating expenses by over a half million dollars compared to the same period last year, while maintaining stable revenue performance. These results reflect the early benefits of our transformational strategy, which is centered around three priorities. Streamlining operations and driving efficiency, strengthening commercial execution in both dental and medical, and advancing our reimbursement and payer strategy to position CompuFlow for broad adoption in pain management. In our dental segment, we made solid progress expanding our direct sales programs in North America and advancing international registrations. for our STA single-tooth anesthesia system. We have also enhanced our omnichannel marketing capabilities and our maturing e-commerce platform continue to drive brand visibility and recurring customer engagement. International dental sales increased year over year, partially offsetting the decline in domestic revenue. On the medical side, utilization of CompuFlow disposables rebounded slightly as we are starting to re-energize current customers ensuring them that we are even more committed than ever as we continue to work on a structured and supported Medicare reimbursement strategy. We are particularly encouraged by feedback from leading pain centers domestically and internationally that are using CompuFlow to improve accuracy, safety, and building confidence in epidural procedures. We also strengthened our organization through the addition of Dr. Dawood Syed to our board of directors. Dr. Syed is one of the country's foremost experts in interventional pain management and serves as division chief of pain medicine at the University of Kansas Medical Center. His appointment deepens our clinical and payer expertise and supports our strategy to accelerate adoption within hospital systems and integrated pain networks. In parallel, we continue to advance our reimbursement strategy for CompuFlow, and as we discussed last quarter, the system has secured Medicare payment rate assignments under CPT code 077T in three jurisdictions, supported by 2MACs, Novitas, and First Coast, that includes large population states like New Jersey, Texas, and Florida. We are now building on that foundation, engaging with additional payers, and expanding our commercial coverage footprint. essential steps for long-term medical growth. In summary, Q3 reflects disciplined execution and tangible progress toward our operational and commercial goals. We are a more efficient organization, our cost structure is leaner, and our strategic priorities are sharply focused on growth and profitability. I'd also like to just point out that we'd like to invite you all to join our Instagram, Facebook, and TikTok pages. Our Instagram page is at the.wan.sta. Our Facebook handle is just thewansta. And our TikTok handle is at the.wan.sta. We continue to put tremendous energy into our omnichannel digital marketing strategy, and we believe that will drive more people to understand who we are as an organization. With that, I would like to turn it over to Keisha Harcum.